The tumor-associated carbohydrate antigen/hapten Thomsen-nouveau (Tn; α-D-GalpNAc-ONH2) was conjugated to a zwitterionic capsular polysaccharide, PS A1, from commensal anaerobe Bacteroides fragilis ATCC 25285/NCTC 9343 for the development of an entirely carbohydrate cancer vaccine construct and probed for immunogenicity. This communication discloses that murine anti-Tn IgG3 antibodies both bind to and recognize human tumor cells that display the Tn hapten. Furthermore, the sera from immunization of mice with Tn-PS A1 contain cytokine interleukin 17 (IL-17A), which is known to possess anti-tumor function and represents a striking difference to an IL-2, and IL-6 profile obtained with anti-PS A1 sera.
Authors thank Dr. Mary Kay Pflum for Jurkat and JurkatTAg cell lines. P.R.A acknowledges Wayne State University for financial support and the National Institutes of Health/National Cancer Institute for an R01 CA 156661 award.
Conflict of interest
The authors declare that they have no conflict of interest.
Avery OT, Goebel WF (1929) Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 50:533–550PubMedCrossRefGoogle Scholar
Landsteiner K, van der Scheer J (1927) On the influence of acid groups on the serological specificity of azoproteins. J Exp Med 45:1045–1056PubMedCrossRefGoogle Scholar
Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308–324PubMedCrossRefGoogle Scholar
Galonic DP, Gin DY (2007) Chemical glycosylation in the synthesis of glycoconjugate antitumor vaccines. Nature 446:1000–1007PubMedCrossRefGoogle Scholar
Velez CD, Lewis CJ, Kasper DL, Cobb BA (2009) Type I streptococcus pneumonia carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation immunology 127:73–82Google Scholar
Jegerlehner A et al (2010) Carrier induced epitomic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 28:5503–5512PubMedCrossRefGoogle Scholar
Zijlstra A, Testa JE, Quigley JP (2003) Targeting the proteome/epitome, implementation of subtractive immunization. Biochem Biophys Res Commun 303:733–744PubMedCrossRefGoogle Scholar
Cobb BA, Wang Q, Tzianabos AO, Kasper DL (2004) Polysaccharide processing and presentation by the MHCII pathway. Cell 117:677–687PubMedCrossRefGoogle Scholar
De Silva RA, Wang Q, Chidley T, Appulage DK, Andreana PR (2009) Immunological responses from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J Am Chem Soc 131:9622–9623PubMedCrossRefGoogle Scholar
Markham RB, Pier GB, Schreiber JR (1991) The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa. J Immunol 146:316–320PubMedGoogle Scholar
Perlmutter RM, Hansburg D, Briles DE, Nicolotti RA, Davie JM (1978) Subclass restriction of murine anti-carbohydrate antibodies. J Immunol 121:566–572PubMedGoogle Scholar
Azeredo da Silveira S et al (2002) Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 195:665–672PubMedCrossRefGoogle Scholar
An Z (2009) Therapeutic monoclonal antibodies: from bench to clinic, Ch 16. Wiley, New JerseyGoogle Scholar
Carcel-Trullols J (2006) Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant. Int J Oncol 28:1173–1183PubMedGoogle Scholar
Fernsten P, Shaw M, Hocker S, Fulghum R, Winfield J (1998) Expression of the sialosyl-Tn epitope on CD45 derived from activated peripheral blood T cells. Immunol Invest 27:323–338PubMedCrossRefGoogle Scholar
Thurnher M, Rusconi S, Berger EG (1993) Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. J Clin Invest 91:2103–2110PubMedCrossRefGoogle Scholar